Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - Reports executive leadership changes and/or officer compensation arrangements at Becton Dickinson & Co. Item 7.01 - Regulation FD Disclosure - Contains material information being disclosed to investors in compliance with Regulation Fair…

Our analysis rates this filing CAUTIOUS. The elevated concern level (6.8/10) reflects a material executive departure creating near-term operational uncertainty, compounded by simultaneous organizational restructuring that appears reactive rather than planned. The loss of a 20+ year executive leading…

Concern level: HIGH (6.8/10). Key factors: High-severity executive departure: Loss of Michael D. Garrison (EVP/President) with 20+ years tenure leading two major segments (Medical Essentials and BioPharma Systems) effective October 2, 2026; Extended leadership vacuum: 2.5+ month transition period (July 19 - September 30, 2026) with outgoing executive in lame-duck capacity creates operational…

Notable risk changes: Unexpected retirement of 20+ year executive (Michael Garrison) leading two major business segments (Medical Essentials and BioPharma Systems) effective October 2, 2026, creating immediate leadership succession risk; Organizational restructuring announced simultaneously with executive departure - BioPharma Systems now reports directly to CEO, suggesting reactive restructuring rather than planned…